Hygieia Extends Series B Round to $22 Million with Participation from Strategic Investors
Summary
This additional investment enables us to explore additional ways to bring d-Nav Technology to more insulin users, for safe, effective insulin therapy, Bashan said.Hygieia is building the nations leading network of diabetes care centers driven by the d-Nav Technology. Hygieias d-Nav Clinical Partnership Program for endocrinology practices treating patients with type 2 diabetes is now in Michigan, Texas, Arizona, and North Carolina, with more states available soon. For more information, contact +1-734-743-2838.Hygieia is the developer of d-Nav\xae, the first FDA-cleared technology to autonomously adjust insulin doses directly to the patient. d-Navs AI-powered technology automatically interprets data and independently initiates insulin management. Studies have shown that nearly 90 percent of people using d-Nav report lower A1C in just three months* without increasing the risk for hypoglycemia**.